132 results about "Malignant lymphoma" patented technology

A therapeutic agent for prostate cancer and malignant lymphoma containing FK228 or a salt thereof as an active ingredient, and a method for evaluating an antitumor effect of a histone deacetylase inhibitor which includes at least a step of treating a test cell with a histone deacetylase inhibitor, a step of measuring change in the expression amount of a specific gene in the test cell before and, after the treatment with the inhibitor, comparing the both expression amounts.

The present invention relates to the application of curcumin in preparing medicine for inverting drug resistance of malignant tumor. The malignant tumor includes oophoroma, cervix cancer, endometrial carcinoma, lung cancer, liver cancer, etc. The effective component of the medicine includes curcumin, demethoxy curcumin, didemethoxy curcumin or their mixture. The medicine consists of the effective component, solvent, stabilizer and co-solvent. It is used to act on drug resisting cell of malignant tumor alone or together with cisplatin or other chemotherapeutic medicine. Compared with traditional drug resistance inverting medicine preparation, the present invention has the advantages of small dosage, high safety and high efficiency.

A diagnostic method for determining the absence or presence of a disease is provided. The method includes assaying the amount and / or types of glycopeptides in a sample from a subject, and comparing these to the amount and types of reference glycopeptides. The method may include the use of a stable isotope label, affinity selection, immunoaffinity chromatography, and glycoproteomics techniques, to identify and quantify changes in glycosylated peptides or glycosylated proteins associated with cancers such as malignant lymphoma or breast cancer, to monitor patient's response to therapy, and to monitor disease recurrence.

The present invention relates to a traditional Chinese medicine which is used for the treatment of cancers, in particular to a Chinese traditional patent medicine for treating lung cancer, cervical cancer, liver cancer, breast cancer, pancreatic cancer and malignant lymphoma. The present invention is characterized in that the present invention includes the raw materials with the following mix ratio by weight: 20 to 40 parts of honeycomb, 15 to 25 parts of oldworld arrowhead corm, 20 to 40 parts of hiraute shiny bugleweed herb, 30 to 50 parts of dahurian patrinia herb, 10 to 20 parts of gecko, 10 to 20 parts of pillbug, 30 to 50 parts of spreading hedyotis herb, 30 to 50 parts of common andrographis herb, 30 to 50 parts of barbed skullcap herb, 20 to 40 parts of common selfheal fruit-spike, 10 to 20 parts of Chinese thorowax root, 10 to 20 parts of figwort root and 10 to 20 parts of ginseng. The present invention has the effects of clearing heat, removing toxicity, promoting blood circulation, removing blood stasis, relieving swelling, resolving hard mass, benefiting qi and easing pain, which is applicable to the treatment of the patients with various mid-advanced tumors; the present invention can alleviate the clinical symptoms of the tumor patients, improve the cellular immune function of the patients, delay the development and the transfer of the cancers, improve the quality of life of the patients and prolong the survival period.

The invention discloses an anti-tumor combination and the application thereof; the anti-tumor combination which includes effective dose of platinum-based chemotherapy and AKT inhibitor and / or p70S6K1 inhibitor has the function of inhibiting the drug resistance of the tumor to the platinum-based chemotherapy, improves the effects of anti-tumor drugs, and can be used for preparing drugs that can resist various tumors, such as lung cancer, ovarian cancer, prostate cancer, breast cancer, stomach cancer, nasopharyngeal cancer, esophageal cancer, malignant lymphoma, head and neck squamous cell carcinoma, thyroid cancer, osteosarcoma, etc.

The invention relates to the technical field of cellular immunity, and discloses a chimeric antigen receptor based on a BMCA nano-antibody sequence and an application thereof, wherein the chimeric antigen receptor includes an extracellular structural domain, a transmembrane structural domain and a primary signal transduction domain. The extracellular structural domain includes an alpaca anti-BCMAantibody or an antigen binding fragment of an alpaca BCMA polypeptide or multiple epitopes. The chimeric antigen receptor is mainly applied in tumor treatment drugs, tumors are blood-related tumor diseases, and the blood-related tumor diseases mainly include various types of leukemia and malignant lymphoma. According to the chimeric antigen receptor based on the BMCA nano-antibody sequence and theapplication thereof, the expression sequence is shorter, and the limited space of a lentiviral vector is saved. The chimeric antigen receptor T cell constructed based on the antibody has better specificity and stronger tumor killing ability.

The invention relates to the technical field of cellular immunity and discloses a construction method and application of a chimeric antigen receptor (CAR) based on a BMCA nano-antibody sequence. The construction method comprises the following steps: step 1: constructing a BMCA single domain antibody library; step 2: screening a BMCA specific nano-antibody sequence; step 3: preparing chimeric antigen receptor T cells. The chimeric antigen receptor is mainly applied to tumor treatment medicines; tumors are tumor diseases related to blood and the tumor diseases related to the blood mainly comprise various leukemia and malignant lymphomas. According to the construction method and application of the chimeric antigen receptor based on the BMCA nano-antibody sequence provided by the invention, the prepared nano-antibody expression sequence is shorter and a limited lentiviral vector space is saved; the chimeric antigen receptor T cells which are constructed based on the antibody have better specificity and a stronger tumor killing capability.

The invention relates to a pharmaceutical composition for treating cancers, a pharmaceutical preparation as well as applications and production methods thereof. The pharmaceutical composition and the pharmaceutical preparation respectively contain a ginseng monomer component, an Astragalus root monomer component, a manyprickle acanthopanax monomer component and a blister beetle monomer component as well as optionally blister beetle monomer derivatives which are added as required. Preferably, the pharmaceutical composition and the pharmaceutical preparation contain 200 to 300 parts by weight of ginseng saponin monomer, 48 to 72 parts by weight of Astragalus root monomer, 60 to 90 parts by weight of manyprickle acanthopanax monomer and 4.2 to 6.3 parts by weight of blister beetle monomer. The pharmaceutical preparation is prepared by the conventional preparation process from the Chinese medicine extracts mentioned above and optionally blister beetle monomer derivatives in addition with adjuvant materials. The pharmaceutical composition and the pharmaceutical preparation thereof, provided by the invention, are used for treating various cancers, such as primary liver cancer, lung cancer, rectal cancer, malignant lymphoma and gynecological malignant tumors, show unexpected curative effects, and can achieve both cancer therapy and immunity enhancement and at the same time reduce the toxicity.

The invention discloses a preparation method of superparamagnetism conductive nano gamma-ferric oxide / polyaniline-dexamethasone sodium phosphate, relating to the technical field of synthesis of superparamagnetism conductive nano gamma-ferric oxide / polyaniline-dexamethasone sodium phosphate. The superparamagnetism conductive nano gamma-ferric oxide / polyaniline-dexamethasone sodium phosphate is prepared by a doping method. The product of the invention can better suspend in water, still has favorable electrochemical activity and electric conduction magnetoconductivity within the pH range of human body environment, and can directionally reach diseased tissues under the regulation and control of an external magnetic field without damaging normal clasmatocyte. The targeted medicine is hopefully applied to treating acute leukemia, malignant lymphoma, connective tissue diseases, rheumatoid arthritis and the like. In addition, the method of the invention is simple, convenient, economical and favourable for industrial production and application.

The invention relates to a Chinese medicine preparation for treating malignant lymphoma, which is an anticancer drug and has distinctive effects. The Chinese medicine preparation is prepared by the following Chinese medicine raw materials in parts by weight: 20-30 parts of ginseng, 1-2 parts of gamboge, 4-6 parts of toad skin, 10-20 parts of curcuma zedoary, 20-30 parts of prunella vulgaris, 10-20 parts of lithospermum, 10-20 parts of coix seeds and 20-30 parts of barbed skullcap herb. A preparation method of the Chinese medicine preparation comprises the following steps of: grinding 20-30 parts of ginseng, 1-2 parts of gamboge and 4-6 parts of toad skin into Chinese medicine powder, mixing the Chinese medicine powder with extracted concentrates of the five Chinese medicine raw materials of 10-20 parts of curcuma zedoary, 20-30 parts of prunella vulgaris, 10-20 parts of lithospermum, 10-20 parts of coix seeds and 20-30 parts of barbed skullcap in liquid phase to prepare pills. The pills have functions of strengthening and consolidating the body resistance, eliminating pathogenic factors, clearing heat and toxic materials, resolving hard lumps, promoting blood circulation and removing blood stasis, and improving human immunity, have the vigor to kill cancer cells and no obvious toxic effects for normal cells, and are used for treating malignant lymphoma.

A Chinese medicine í«Compound telini fly capsuleí» for treating primary liver cancer, lung cancer, rectum cancer, lymph cancer, and gynecologic cancer is prepared from 10 Chinese-medicinal materials including ginseng, telini fly, astragalus root, etc. Its preparing process is also disclosed.

The invention belongs to medical domain; it has disclosed a compound medicine that contains cantharidin orits derivates and at least one kind of medicine that can improve the immunity, the preparing method and application is also mentioned in the invention. The medicine that can improve immunity is chosen from one kind or various kinds of lentinan, ganoderma and hoelen. The medicine can be used to treat liver cancer, esophageal cancer, carcinoma of gastric cardia, lung cancer, malignant lymphoma and low blood corpuscle; it can also be used to treat hepatitis, cirrhosis or HB virus; it can be used as preoperative drug for cancer operation or be used in combination chemotherapy with the function of coordinated synergistic action. The product in the invention has good stability and the effects have been greatly improved than the single application of Norcantharidin, lentinan, ganoderma and hoelen. The medicine can be made into any medically acceptable dosage with any medically acceptable accessories so it has wide prospects.

In order to more accurately analyze a change in the complicated gene copy number in malignant lymphoma and identify a region affected by an important genomic aberration in greater detail so that the results can be used in diagnosing the type of disease and performing prognosis, genome-wide array CGH is carried out and thus human chromosome 136.23 to p36.32, human chromosome 1 q42.2 to q43, human chromosome 2 p11.2, human chromosome 2 q13, human chromosome 17 p11.2 to p13.3, and human chromosome 19 p13.2 to p13.3 are identified.

The invention discloses a traditional Chinese medicine composition for treating malignant lymphoma. The composition comprises Angelica, Ligusticum wallichii, radix paeoniae rubra, rehmanniae radix, Radix Scrophulariae, edible tulip, airpotato yam, seaweed, kelp, prunella vulgaris, oyster, Paris polyphylla, trigone, rhizoma curcumae, Rhizoma Cyperi, scorpion, centipede, semen brassicae, pericarpium citri reticulatae viride, Fructus aurantii and Radix bupleuri. The invention uses methods of reducing phlegm and resolving masses, and regulating qi and dissipating stasis. Aiming at the etiology and pathogenesis of malignant lymphoma, the invention provides a novel treatment concept: occurrence, development and ending of malignant lymphoma lay in qi. Qi stagnation causes blood stasis, and blood stasis causes phlegm accumulation, and phlegm accumulation causes abdominal masses, which lead to tumor. Accordingly, the invention adopts a group of traditional Chinese medicines which can permeate qifen. Rectifying qi can smooth the liver, and guiding qi downward can realize smoothness, and relieving stagnant qi can dissipate stasis. Ancient medicine believes in invigorating the spleen to eradicate source of phlegm, and today the invention utilizes pectoral qi to eliminate the foundation of tumor, so as to treat lymphatic cancer from the foundation; and coupled with medicines for dissipating phlegm, the lymphatic cancer can be cured. All parties are played together to smooth the liver, rectify qi, draw out poison, relieve swelling, break masses, dissipate stasis, benefit water-dampness, relieve phlegm coagulation, reduce cancer, strengthen the body resistance to eliminate pathogenic factors and resist cancer.

The invention relates to a Chinese herbal medicine combination for malignant lymphomas and the preparation method, made of prunella vulgaris, rhizoma ligustici wallichii, seeds of brassica alba, nutgrass galingale rhizome, gleditsia sinensis sting, rhizome arisaematis, ephedra, cortex moutan, poria cocos, lanceolata, liquorice root, dried green orange peel, bupleurum, honeysuckle, dandelion, rhizoma zedoariae and / or acceptable carrier in pharmacy. The Chinese herbal medicine combination has the effect of warming for resolving cold coagulation, eliminating phlegm and detoxification, smoothing the liver and dispelling melancholy, and notifying qi and blood, and is used for painless enlargement of superficial lymph node, fever, night sweat and other symptoms caused by malignant lymphomas.

The invention discloses an antineoplastic medicinal composition containing at least ginseng or its extract, ophiopogon root or its extract, schisandra fruit or its extract, the process for preparation and use thereof, wherein the medicament is one or two selected from cantharidin or derivatives or analogues, and toad venoms. The composition can be used for treating hepatic carcinoma, esophagus cancer, cardiac cancer, lung carcinoma, breast cancer, intestinal cancer, malignant lymphoma, hepatitis and cirrhosis.

A preparing method of drug carrying nanoparticles for targeted treatment of malignant lymphoma is disclosed. An amphoteric polymer PEG-PLGA having good biocompatibility is adopted as a carrier center,a hydrophobic segment covers and carries a hydrophobic drug that is adriamycin (DOX), and carboxyl exposed at the outer end is activated through a chemical reaction and is boned with a nucleic acid aptamer having amino. The drug carrying nanoparticles are rapidly delivered to a tumor position by utilizing the targeting function of the nucleic acid aptamer, and the drug is released slowly by utilizing the sustained release function of the PEG-PLGA nanoparticles, thus achieving long-acting efficient treatment of the malignant lymphoma, and reducing side effects caused by common therapies such as chemotherapy.

An object of the present invention is to provide a method for determining whether a subject suffers from malignant lymphoma or leukemia and an agent for treating and / or preventing the disease. The present invention relates to a method for assisting in determining whether a subject suffers from, or is likely to suffer from malignant lymphoma or leukemia, comprising: a detection step of detecting at least one of a fusion mutation of a DUX4 gene, an overexpression of a DUX4 gene, and a fusion mutation of an MEF2D gene; and a determination step of determining that the subject suffers from or is likely to suffer from the disease when at least one of the fusion mutations or the overexpression is detected. Moreover, the present invention relates to a pharmaceutical composition comprising a DUX4 inhibitor as an active ingredient, for treating and / or preventing malignant lymphoma or leukemia in a subject having a fusion mutation of a DUX4 gene and an IGH or IGL gene and / or overexpression of a DUX4 gene.

The invention discloses a broad-spectrum antineoplastic agent, relating to a micro-emulsified injection with Sodium Demethylcantharidate , which is suitable for the curing of patients with a plurality of tumors such as primary liver cancer, lung cancer, esophagus cancer, nasopharyngeal cancer, malignant lymphoma, bladder cancer, gynecologic malignant tumor and leukopenia, hepatitis, liver cirrhosis and hepatitis b virus, the invention also discloses the preparation method of the medicine, which is characterized in having good curing effect and low adverse reaction.

The invention discloses a traditional Chinese medicine preparation for treating lymphoma. The traditional Chinese medicine preparation comprises 3-5g of rhizoma sparganii, 4-10g of rhizoma curcumae, 2-4g of rhizoma pleionis, 3-5g of raw radix astragali, 4-8g of radix scrophulariae, 5-9g of prunella spike, 3-9g of Chinese angelica, 4-10g of bulbus fritillariae thunbergii, 2-6g of arisaema cum bile, 3-7g of red sage root, 4-10g of dragon's blood, 2-4g of ligusticum wallichii, 5-9g of Chinese polyphaga, 2-4g of centipede, 1-3g of dung beetle, 4-10g of red peony root, 1-3g of turtle shell, 2-6g of hedyotis diffusa, 4-10g of glaucescent fissistigma root, 2-4g of radix achyranthis bidentatae, 5-9g of fructus psoraleae, 4-10g of felwort, 3-9g of radix curcumae, 4-10g of rhizoma cyperi, 3-7g of muskroot-like semiaquilegia root, 4-10g of phellodendron, 5-9g of rhizoma smilacis glabrae, 4-12g of honeysuckle flower, 3-9g of dandelion and 6-10g of licorice root. The traditional Chinese medicine preparation is prepared from pure natural traditional Chinese medicines and has a unique effect of treating malignant lymphoma.

The present invention relates to conjugate of 3, 7, 10-trisubstituent silatrane and 5-FU, which may be used in preparing medicine for treating leukemia, liver cancer, rectum cancer, gastric cancer, breast cancer and other tumors, and has the structural formula as shown.

Cytotropic Heterogeneous Molecular Lipids (CHML) are used to treat patients with multiple cancers. Numerous studies have been conducted in cellular, animal, pre-clinical and clinical trials. Results showed that CHML, as a biological molecular missile, can easily penetrate through the target cancerous cells to perform programmed cancer cell death (cancer apoptosis). Furthermore, CHML has produced anti-cancer angiogenesis and induced immune function increase. CHML was used to treat 592 patients with cancers in clinical trials. Results confirmed the following advantages of CHML treatment: non-toxicity, high response rate, high quality of life, and high survival rate for these patients. The protocols include local injection, arterial drip and intravenous drip to treat cancers of liver, lung, skin, breast, brain glioma, colon and rectum, stomach, head and neck, leukemia, malignant lymphoma, sarcoma, malignant melanoma, myeloma, and metastasis cancers, etc.

Disclosed is a hematopoietic stem cell proliferation inducing agent which comprises a pulverized product of placenta-constituting cells as an active ingredient and can induce / proliferate a hematopoietic stem cell in the peripheral blood. Since the proliferation inducing agent can induce / proliferate a hematopoietic stem cell to increase the amount of hematopoietic stem cells in the peripheral blood, it becomes possible to ensure the increase in the amount of hematopoietic stem cells in the peripheral blood. The proliferation inducing agent can be used for the prevention and treatment of various diseases which are caused or believed to be caused by the decrease in the amount of hematopoietic stem cells (e.g., leukemia, malignant lymphoma, aplastic anemia, Alzheimer's disease, Parkinson's disease, dilated cardiomyopathy, myocardial infarction) and produces extremely small adverse side effects.

The invention relates to screening and a preparation method and application for an antibody medicament for malignant lymphoma and autoimmune diseases, and discloses a lymphoma specificity humanized antibody for resisting HLA-DR10, a person and whole person monoclonal antibodies and segments thereof, and a radioactive isotope labeling antibody thereof including a heavy chain and a light chain, wherein the heavy chain contains a constant region, a heavy chain variable region amino acid sequence is SEQID NO:1, the light chain contains a constant region, a light chain variable region amino acid sequence is SEQID NO:2, and the heavy chain is connected with the light chain through a disulfide bond. The invention obtains NSO and CHO engineering cell strains of stable high-level expression lymphoma specificity humanized, person and the whole person monoclonal antibodies (chlym-1 antibody) for resisting the HLA-DR10, adopts a serum-free high density culture technique so that the expression of the chlym-1 is more than 500 milligrams per liter, and discloses application of the monoclonal antibodies in treating the malignant lymphoma and the autoimmune diseases.

A screening method is provided for antibody specifically recognizing naturally-occurring form of human autotaxin in a state in which it is present in the body without being denatured, comprising the steps of: binding a binding factor capable of capturing a candidate antibody of the antibody to a solid phase; binding the candidate antibody of the antibody to the binding factor; allowing naturally-occurring form of human autotaxin to react on a system in which the candidate antibody has reacted; and selecting an antibody that specifically recognizes the naturally-occurring form of human autotaxin by using as an indicator thereof the binding strength of the naturally-occurring form of human autotaxin to the antibody. Moreover, a detecting method for malignant lymphoma is provided comprising: measuring the concentration of autotaxin in a human specimen, and judging to be a malignant lymphoma in the case that value exhibits a significantly higher value than normal values comprised of measured values from normal healthy subjects.

The invention discloses a traditional Chinese medicinal composition for treating scrofula and lymphoma, which comprises the following raw materials in parts by weight: 5 to 15 parts of cantharides, 55 to 65 parts of Fineleaf Schizonepeta Herb, 55 to 65 parts of semen pharbitidis, 55 to 65 parts of the larva of silkworm with botrytis, 55 to 65 parts of worm grass and 190 to 210 parts of talc, and the traditional Chinese medicinal composition can be made into tablet, capsule or oral-taken liquid. Functions of the above raw materials supplement and complement each other, the functions such as warming cold accumulation, reducing phlegm and detoxicating, soothing the liver, enriching the blood and the like can be realized, and the composition has good curative effect on scrofula and the lymphoma, has strong inhabitation effect on the lymphaden shift after the surgical operation, and has strong inhabitation effect on other cancers such as liver cancer, gastric cancer, breast cancer, lymph cancer and lymphoma. Compared with the prior art, the traditional Chinese medicinal composition has short period of treatment, remarkable curative effect, convenience and safety, is easy to obtain the raw material, is convenient to use, and is free from toxicity and side effect.

It is intended to clarify the CD20 amino acid sequence and its gene sequence which are essentially required in constructing an anti-CD20 antibody useful in treating animal malignant lymphoma. It is also intended to provide a method of diagnosing canine malignant lymphoma by using the gene sequence. Using monocytes in canine blood as a sample, mRNA is obtained and the full base sequence of canine CD20 gene (SEQ ID NO:2) is determined. Based on this sequence, its amino acid sequence (SEQ ID NO:1) is determined. Comparing the homologies with human and mouse CD20 genes and amino acid sequences, it is identified as canine CD20 gene. Moreover, a primer specific to the canine gene is constructed and the expression of the CD20 gene in a sample is examined, thereby giving a method of diagnosing canine B lymphocyte-origin malignant lymphoma.

The invention provides an icariside I compound and a derivative and a pharmaceutical salt. A structure formula is shown as a formula I in the description. The compound, the derivative, the pharmaceutical salt or the composite is used for preparing medicine capable of being used for preventing, relieving or treating tumor diseases. The tumor includes liver cancer, lung cancer, colon cancer, ovariancancer, bile duct cancer, malignant lymphoma, liver cancer, bladder cancer and prostate cancer. The icariside I compound has obvious effects in aspects of improving the human immunity, improving thehuman IFN-gamma level, improving the apoptin NOXA expression and the like. Through in vivo experiments on mice and liver cancer cells (H22 cells and hepg2 cells) experiments, the results prove that the icariside I can obviously inhibit the tumor growth.

A compound blistering beetle tablet for treating primary liver cancer, rectum cancer, malignant lymphoma and malignant tumor of woman is prepared through pulverizing 4 Chinese-medicinal materials including ginseng, crushing 5 Chinese-medicinal materials including astragalus root, decocting three times, concentrating and spray drying, extracting from Chinese blistering beetle in chloreform, concentracting, grinding bear gall, mixing all together, adding additive, mixing tabletting and coating.